Close this search box.

Kentucky House passes bill to regulate Delta-8 THC products


Kentucky House passes bill to regulate Delta-8 THC products

A bill to regulate Delta-8 THC sped through the House of Representatives on Thursday, writes Liam Niemeyer of the Kentucky Lantern for Marijuana Moment.

House Bill 544, sponsored by Rep. Rebecca Raymer, R-Morgantown, was a bill making technical language changes related to the Cabinet for Health and Family Services. The new bill language directs the Cabinet for Health and Family Services to immediately begin the process of regulating Delta-8 THC and “other hemp-derived substances.”

Katie Moyer, president of the Kentucky Hemp Association, stated: “We have sort of a ‘wild west’ situation. It’s a gray area. Delta-8 is being sold around the state, and it’s being sold in gas stations, health food stores.

“But it’s coming from ‘who knows where.’ We’re not surely getting it from Kentucky producers who are growing it here, who we can go visit their store, their facility.”


Raphael Mechoulam, ‘father of cannabis research’, dies at 92

Hebrew University Professor Raphael Mechoulam, considered the “father of cannabis research,” has died in Israel at age 92, reports MJ Biz Daily.

Mechoulam and his team of researchers were the first to isolate delta-9 THC in the 1960s, the psychoactive component of cannabis and Mechoulam has also designed and synthesized several novel cannabinoids with therapeutic potential.

The publication notes he was nominated for more than 25 academic awards, including:

  • The Heinrich Wieland Prize in 2004.
  • An honorary doctorate from Complutense University in Madrid in 2006.
  • The Israel Prize in Exact Sciences, Chemistry, in 2000.

“Most of the human and scientific knowledge about cannabis was accumulated thanks to Prof. Mechoulam,” Hebrew University President Asher Cohen said in a statement.


Best medical cannabis stocks to buy

The Motley Fool explores what you need to know about the growing medical cannabis sector before you invest.

The publication highlights that the global medical marijuana market is projected to grow at an annualized rate of almost 18% through 2028, and investors who opt to buy individual medical cannabis stocks can choose among Canadian or U.S. companies.

The Motley Fool’s top buys for 2023 include:

  • Village Farms International (NASDAQ:VFF).
  • Jazz Pharmaceuticals (NASDAQ:JAZZ).
  • Trulieve Cannabis (OTC:TCNNF).
  • Innovative Industrial Properties (NYSE:IIPR).

Before investing in any stock, investors should consider financial performance, growth opportunities and competitive positions.


Expanding into Europe in 2023?

This month, Prohibition Partners will be launching Edition 8 of The European Cannabis Report, our flagship industry report and the most widely-read resource in the European cannabis industry.

Later in May, Cannabis Europa 2023 takes place in London which will see over 1,500 delegates inside the iconic Barbican Centre to share learnings, network, and move the industry forward. After last year’s success, we will once be holding a small, curated expo alongside the conference.

Talk to our sales team about positioning your company as an authority in the European market.

Sponsor European Report >>
Get involved with Cannabis Europa >>

Related Posts

Related Posts


Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you


Browse by Tags




© 2023 Prohibition Holdings Ltd. All Rights Reserved.


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?